HEART FAILURE PATIENTS REVIEW 1
NURS 615
Current Pharmacological Therapies In Heart Failure Patients Review
Maryville University
NURS 615: Advanced Pharmacotherapeutics
For this assignment, I chose the article, Current pharmacological therapies in heart
failure patients. The article by Muiesan et al. (2017) examines the health and social-economic
implications of heart failure in the healthcare system and the current pharmacological
interventions for treating the condition. Treatment guidelines of heart failure in the United States
and Europe propose clinical differentiation between heart failure with reduced ejection fraction
(HFrEF) and heart failure with preserved ejection fraction(HFpEF). Pharmacological
interventions guidelines for HFrEF are mostly uniform in the United States and Europe. The only
difference occurs in the indication to second-line agents, namely ivabradine, hydralazine-
isosorbide dinitrate in the treatment of HFrEF. For patients suffering from chronic heart failure,
treatment guidelines require a dosage comprising a combination of angiotensin-converting
enzyme (ACE)-I (or angiotensin receptor blocker (ARB) in cases where ACE is not tolerated), a
beta-blocker and mineralocorticoid antagonist(MRA) (Muiesan et al., 2017).
In patients suffering from heart failure with preserved ejection fraction(HFpEF),
treatment guidelines require careful screening for cardiovascular and non-cardiovascular
comorbidities. The screening helps improve health outcomes, promoting better control of
symptoms and patient's well-being associated with non-cardiovascular conditions such as chronic
obstructive pulmonary disease, diabetes, hypertension, and obesity in addition to prevention of
NURS 615
Current Pharmacological Therapies In Heart Failure Patients Review
Maryville University
NURS 615: Advanced Pharmacotherapeutics
For this assignment, I chose the article, Current pharmacological therapies in heart
failure patients. The article by Muiesan et al. (2017) examines the health and social-economic
implications of heart failure in the healthcare system and the current pharmacological
interventions for treating the condition. Treatment guidelines of heart failure in the United States
and Europe propose clinical differentiation between heart failure with reduced ejection fraction
(HFrEF) and heart failure with preserved ejection fraction(HFpEF). Pharmacological
interventions guidelines for HFrEF are mostly uniform in the United States and Europe. The only
difference occurs in the indication to second-line agents, namely ivabradine, hydralazine-
isosorbide dinitrate in the treatment of HFrEF. For patients suffering from chronic heart failure,
treatment guidelines require a dosage comprising a combination of angiotensin-converting
enzyme (ACE)-I (or angiotensin receptor blocker (ARB) in cases where ACE is not tolerated), a
beta-blocker and mineralocorticoid antagonist(MRA) (Muiesan et al., 2017).
In patients suffering from heart failure with preserved ejection fraction(HFpEF),
treatment guidelines require careful screening for cardiovascular and non-cardiovascular
comorbidities. The screening helps improve health outcomes, promoting better control of
symptoms and patient's well-being associated with non-cardiovascular conditions such as chronic
obstructive pulmonary disease, diabetes, hypertension, and obesity in addition to prevention of
